Trials on MDMA for PTSD treatment have faced significant criticism for ignoring worsening suicidal tendencies among participants and allegations of bias in reporting results. Multiple participants reported feeling pressured to provide positive feedback despite experiencing negative effects like increased depression and suicidal thoughts. Lykos Therapeutics, the company behind the trials, has disputed these claims, maintaining the study's integrity. Amid these controversies, 80 bipartisan members of Congress have urged President Biden and the FDA to consider MDMA-assisted therapy for PTSD, emphasizing the need for effective treatments for veterans. The FDA's decision on the approval of MDMA for PTSD treatment is expected soon, with implications for future psychedelic therapies. The agency's independent panel has already recommended against approval due to the reported issues in the trials.